Dr. Dallabrida recognized for driving innovation in patient-driven eData technologies that improve clinical research
September 04, 2014
BOSTON, Mass. and GENEVA, Switzerland – announced that Vice President of Clinical Science and Consulting Services Dr. Susan Dallabrida will present “Effective Use of Electronic Patient Reported Outcomes (ePRO) in Multiple Myeloma” at the ESMO 2014 Congress, 26-30 September in Madrid. PHT is the leading provider of technologies used to collect patient-driven eData for clinical research.
The ESMO 2014 Congress is sponsored by the European Society for Medical Oncology, the leading European professional organisation representing medical oncologists.
The poster abstract will also be published in the ESMO 2014 Congress Abstract Book, a supplement to the official ESMO journal Annals of Oncology.
The poster was developed by members of the PHT Clinical Science Team, with 100+ years of collective experience in ePROs and COAs:
Susan M. Dallabrida PhD, Vice President, Clinical Science & Consulting – Dr. Dallabrida has over 21 years of experience as a senior scientist, consultant and leader in clinical research and development, trial design and strategy, and product development. She has significant regulatory experience for biologics and small molecules.
Sarah Tressel Gary PhD, Senior Science Advisor – Dr. Gary has significant experience working with PRO development and validation studies, questionnaire design and working with developers of standardized instruments. She is experienced in migration studies including cognitive debriefing and usability testing in a number of therapeutic areas.
PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for better clinical research. The PHT electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from the latest mobile devices. PHT scientific, regulatory and technological expertise combined with quality outcomes data enable clients to make research decisions with confidence. Sponsors and CROs have leveraged the PHT Patient Suite in 650+ trials resulting in 17+ regulatory approvals